Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$11.21 USD

11.21
12,479,121

+0.12 (1.08%)

Updated Aug 12, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Generic Drugs

Trades from $1

Zacks News

TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.

Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View

TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA

Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.

    AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints

    AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.

    TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates

    Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.

    Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals

    Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals

    Indrajit Bandyopadhyay headshot

    3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

    The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

    Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down

    Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.

    J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug

    J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.

    Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance

    The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.

    3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

    The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

    Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised

    Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.

    Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

    Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

    TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

    TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.

    Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?

    Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

    Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

    TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

    TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.

    Indrajit Bandyopadhyay headshot

    3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

    The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

    Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

    Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

    Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

    Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

    TEVA Stock Declines Despite Q4 Earnings and Sales Beat

    TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.